11/5/2026

speaker
Conference Operator
Operator

Greetings and welcome to the Artivian third quarter 2026 earnings call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Brian Johnston from the Gilmartin Group. Thank you. You may begin.

speaker
Brian Johnston
Investor Relations, Gilmartin Group

Good afternoon and thank you for joining the call today. Joining me from our TIVIANS management team are Pat Mackin, CEO, and Lance Berry, COO and CFO. Before we begin, I would like to make the following statements to comply with the safe harbor requirements of the Private Securities Litigation Reform Act of 1995. Comments made on this call that look forward in time involve risks and uncertainties and are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements include statements made as to the company's or management's intentions, hopes, beliefs, expectations, or predictions of the future. These forward-looking statements are subject to a number of risks and uncertainties, estimates, and assumptions that may cause actual results to differ materially from these forward-looking statements. Additional information concerning certain risks and uncertainties that may impact these forward-looking statements is contained from time to time in the company's SEC filings as well as the press release that was issued earlier today. You can also find a brief presentation with details highlighted on today's call on the investor relations section of the IRTVING website. Lastly, I'd like to remind you to please refer to our press release published earlier today for information regarding our non-GAAP results, including the reconciliation of these results to our GAAP results. Unless otherwise stated, all of our comments in today's call will be using our non-GAAP results. Additionally, all percentage changes discussed will be on a year-over-year basis. Revenue growth rates will be the adjusted constant currency rates, and expenses as percentages of sales will be based on adjusted revenues. With that, I'll turn it over to the NCEO, Pat Mackin.

speaker
Pat Mackin
CEO, Artivion

Hey, thanks, Brian, and good afternoon, everybody. In the third quarter, we delivered total constant currency revenue growth of 9%. and adjusted EBITDA decline of 8% year-over-year. These results reflect continued execution of our strategy designed to deliver long-term profitable growth through an expanding and clinically differentiated product portfolio. From a product category perspective, Stancraft revenues grew 12% on a constant currency basis in the third quarter compared to the same period last year. This performance is consistent with the growth rate we report in Q2, and notably came against a tougher AMDS prior year comparison this quarter. On AMDS, the number of US implants increased from the second quarter, which we believe reflects the impact of our recent PMA approval and our efforts to drive adoption of this new technology. We continue to view implant increases as the most important indicator of AMDS adoption, given it reflects the real world use and the user experience that will drive growth in the long term. Meanwhile, U.S. AMBF's set sales remain challenged. We view this dynamic as administrative and transient. We remain confident that the set sales will build as the benefits of our initiatives aimed at mitigating the barriers associated with the upfront $100,000 investment for starter sets takes hold. Now for a brief update on Nexus. We believe our preparations for U.S. commercial launch early next year are progressing well. Through the remainder of 2026, our focus will remain on expanding manufacturing capacity and building inventory, working through value analysis committee processes, augmenting our U.S. sales team, and preparing for broader surgeon training. Interest across the clinical community has continued to build, and we look forward to conducting our first surgeon training event in December. In the meantime, we're continuing to support some U.S. cases on a limited basis. Feedback from surgeons using the technology has been excellent, and we believe there's a significant demand for Nexus ahead of the U.S. launch, which is expected in January of 2027. We look forward to providing additional updates on launch timing and readiness as we get closer. Ultimately, we see our comprehensive StentGraph portfolio as a foundational component of our growth strategy. We believe our competitive advantages and surgeon demand will drive greater sustainable adoption and utilization over the medium term. Turning to ONIX, our third quarter ONIX revenue grew 13% year-over-year on a cost of currency basis. This performance is driven by continued mid-teens revenue growth in the U.S., partially offset by lower growth internationally, which we view as a normal quarterly variation. Importantly, we exited the quarter in a strong supply position as a result of the investments we've made in our Austin manufacturing facility. We believe that puts us in a stronger position to meet demand globally, as we close the year and enter 2027 with a product that we believe is the best aortic valve on the market for patients under the age of 65. Tissue processing revenue declined 0.3% year over year on a constant currency basis due to a difficult prior year comp, but was ahead of our expectations for the quarter. Regarding BioGlue, revenues increased modestly on a constant currency basis compared to the same period last year. As we've discussed during our previous calls this year, This product line carries a meaningful amount of stocking distributor orders, which creates some normal quarter-to-quarter variability. Importantly, our long-term outlook for BioGlue remains unchanged. Lastly, revenue in our other category grew 93% year-over-year driven by per-clot. As we previously noted, our transitional manufacturing and supply agreement with Baxter will expire in February of 2027. and we expect the final purchase to be made in December of this year. Overall, the per-clot transaction has been a significant positive as it allowed us to turn a non-strategic asset into cash. Although it has taken us longer than we would have hoped to get to this point, we're glad to be reaching the end of this transition services and to be able to completely focus on our ongoing business. Turning to our pipeline, we continue to make progress on the Artisan Clinical Trial for our SIBO LSA product. We now have 56 patients enrolled in that trial, which is a non-randomized clinical trial, up to 132 patients in the U.S. and Europe, and up to 30 centers for the treatment of aortic dissection and aneurysm in the aortic arch. We continue to anticipate completing enrollment in mid-27. We are optimistic that the trial will be successful based in part on the positive clinical results from our current generation frozen allocin trunk, called the Vita Open Neo, which we sell outside the U.S. Following a one-year period of follow-up and assuming the trial meets its endpoints, we anticipate FDA approval for our SIBO LSA in 2029, unlocking an incremental $80 million opportunity in the U.S. market. In conclusion, we continue to advance our overall strategy in the third quarter while generating solid financial and operational results. Stancraft's grew 12% for the second consecutive quarter, Next, as launch preparations are on track, we exit the quarter with a much stronger supply position on ONIX. We continue to believe the fundamentals that underpin our growth strategy remain strong, a comprehensive, clinically differentiated portfolio, a focused commercial organization, and a pipeline that stands to expand our total adjustable market over time. With that, I'll now turn the call over to Lance.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API